A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3
暂无分享,去创建一个
Dan Lu | Zhen-ping Zhu | K. Persaud | Xenia Jimenez | Larry Witte | Zhenping Zhu | X. Jimenez | H. Miao | Meilin Liu | Hua-Quan Miao | Kris Persaud | L. Witte | Laura Brennan | D. Lu | Meilin Liu | Laura A. Brennan | Kris Persaud
[1] Rachel Jones. Ecstasy danger hits the headlines , 2002, Nature Reviews Neuroscience.
[2] S. Rafii,et al. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity , 2003, Leukemia.
[3] K. Alitalo,et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[4] K. Alitalo,et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis , 1999, British Journal of Cancer.
[5] P. Hewett,et al. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. , 2002, Cancer research.
[6] S. Nishikawa,et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. , 2000, Blood.
[7] M. Karkkainen,et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. , 2001, Cancer research.
[8] Zhen-ping Zhu,et al. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C , 2004, Journal of Cell Science.
[9] P. Bohlen,et al. Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Human Recombinant Bispecific Antibody* , 2004, Journal of Biological Chemistry.
[10] D. Hicklin,et al. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. , 1998, Cancer research.
[11] P. Bohlen,et al. Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies* , 2000, The Journal of Biological Chemistry.
[12] N. Ferrara. Vascular endothelial growth factor: molecular and biological aspects. , 1999, Current topics in microbiology and immunology.
[13] S. Hirakawa,et al. The Formation of Lymphatic Vessels and Its Importance in the Setting of Malignancy , 2002, The Journal of experimental medicine.
[14] K. Alitalo,et al. Lymphatic Vessels as Targets of Tumor Therapy? , 2001, The Journal of experimental medicine.
[15] VEGF receptor signal transduction. , 2003, Science's STKE : signal transduction knowledge environment.
[16] K. Alitalo,et al. Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-CΔNΔC- and VEGF-A-induced angiogenesis in vitro , 2003 .
[17] P. Bohlen,et al. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. , 2002, Current cancer drug targets.
[18] K. Shitara,et al. and surface marker for the lineage of monocyte-macrophages in humans Flt-1 , vascular endothelial growth factor receptor 1 , is a novel cell , 2001 .
[19] S. Stacker,et al. Localization of vascular endothelial growth factor‐D in malignant melanoma suggests a role in tumour angiogenesis , 2001, The Journal of pathology.
[20] Stephen J Boyer,et al. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. , 2002, Current topics in medicinal chemistry.
[21] Peter Bohlen,et al. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. , 2001, Cancer research.
[22] K.,et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] R. Jain,et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.
[24] B. Ruggeri,et al. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. , 2004, Current medicinal chemistry.
[25] L. Ellis,et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. , 2002, European journal of cancer.
[26] L. Ellis,et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors , 2001, British Journal of Cancer.
[27] G. Neufeld,et al. Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] D. Weng,et al. Angiozyme: A Novel angiogenesis inhibitor , 2001, Current oncology reports.
[29] J. Vaillant,et al. Vegf, vegf‐B, vegf‐C and their receptors KDR, FLT‐1 and FLT‐4 during the neoplastic progression of human colonic mucosa , 2000, International journal of cancer.
[30] H. Dvorak. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] M. Karkkainen,et al. Vascular endothelial growth factor receptor-3. , 1999, Current topics in microbiology and immunology.
[32] D. Ruiter,et al. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. , 2002, Cancer research.
[33] K. Alitalo,et al. VEGF‐C and VEGF‐D expression in neuroendocrine cells and their receptor, VEGFR‐3, in fenestrated blood vessels in human tissues , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[34] S. Rafii,et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.
[35] K. Alitalo,et al. Role of lymphangiogenic factors in tumor metastasis. , 2004, Biochimica et biophysica acta.
[36] Peter Bohlen,et al. Tailoring in Vitro Selection for a Picomolar Affinity Human Antibody Directed against Vascular Endothelial Growth Factor Receptor 2 for Enhanced Neutralizing Activity* , 2003, Journal of Biological Chemistry.
[37] Napoleone Ferrara,et al. VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.
[38] Robert E. Ferrell,et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema , 2000, Nature Genetics.
[39] K. Alitalo,et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, American Journal of Pathology.
[40] D. Hicklin,et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.